The shadow of generic rivalry has consistently loomed over copyright’s iconic drug, Viagra, sparking questions about the outlook of similar drug investments. While early times saw impressive profits, the intellectual property lapse has opened the way for less expensive substitutes, possibly reducing earnings and posing a genuine hazard for stakeh